Nuclera

Nuclera, a biotechnology company, has announced a $12 million financing extension, raising its total Series C funding to $87 million. The funding, led by Elevage Medical Technologies and Jonathan Milner, aims to enhance the company's eprotein discovery system by integrating antibody expression and validation capabilities. This advancement addresses the industry's need for scalable, high-quality datasets for AI-driven biologics discovery, ultimately accelerating therapeutic timelines.

Biotech firm Nuclera has raised an additional $12 million, bringing its total Series C funding to $87 million. The extension round was led by Elevage Medical Technologies and Jonathan Milner, with participation from existing investors including British Business Bank and GK Goh. Nuclera's eProtein Discovery platform streamlines protein expression, purification, and screening for drug discovery, addressing the need for scalable, high-quality datasets in biologics research. The funding will enhance the platform's capabilities, accelerating therapeutic discovery timelines.